Europe Antibody Drug Conjugates Market to 2030 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Antibody Drug Conjugates Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Antibody Drug Conjugates Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Strategic Investments by Key Players

5.2 Market Opportunities

5.2.1 Expansion into New Indications

5.3 Future Trends

5.3.1 Expanding Clinical Trial Pipeline

5.4 Impact of Drivers and Restraints

6. Europe Antibody Drug Conjugates Market Regional Analysis

6.1 Europe Antibody Drug Conjugates Market Overview

6.2 Europe Antibody Drug Conjugates Market Revenue 2020-2030 (US$ Million)

6.3 Europe Antibody Drug Conjugates Market Forecast Analysis

7. Europe Antibody Drug Conjugates Market Analysis – by Technology

7.1 Cleavable Linker

7.1.1 Overview
7.1.2 Cleavable Linker: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Non-cleavable Linker

7.2.1 Overview
7.2.2 Non-cleavable Linker: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Antibody Drug Conjugates Market Analysis – by Application

8.1 Blood Cancer

8.1.1 Overview
8.1.2 Blood Cancer: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

8.2 Breast Cancer

8.2.1 Overview
8.2.2 Breast Cancer: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

8.3 Ovarian Cancer

8.3.1 Overview
8.3.2 Ovarian Cancer: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

8.4 Urothelial Cancer

8.4.1 Overview
8.4.2 Urothelial Cancer: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

9. Europe Antibody Drug Conjugates Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies

9.1.1 Overview
9.1.2 Urothelial Cancer: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

9.2 Retail Pharmacies

9.2.1 Overview
9.2.2 Urothelial Cancer: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

9.3 Online Pharmacies

9.3.1 Overview
9.3.2 Urothelial Cancer: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

10. Europe Antibody Drug Conjugates Market – Europe Analysis

10.1 Europe

10.1.1 Europe Antibody Drug Conjugates Market Breakdown, by Key Country, 2023 and 2030 (%)
10.1.1.1 Europe Antibody Drug Conjugates Market – Revenue and Forecast Analysis – by Country
10.1.1.1 UK: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.1.1 UK: Europe Antibody Drug Conjugates Market Breakdown, by Technology
10.1.1.1.2 UK: Europe Antibody Drug Conjugates Market Breakdown, by Application
10.1.1.1.3 UK: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel

10.1.1.2 Germany: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.2.1 Germany: Europe Antibody Drug Conjugates Market Breakdown, by Technology
10.1.1.2.2 Germany: Europe Antibody Drug Conjugates Market Breakdown, by Application
10.1.1.2.3 Germany: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel

10.1.1.3 France: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.3.1 France: Europe Antibody Drug Conjugates Market Breakdown, by Technology
10.1.1.3.2 France: Europe Antibody Drug Conjugates Market Breakdown, by Application
10.1.1.3.3 France: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel

10.1.1.4 Russia: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.4.1 Russia: Europe Antibody Drug Conjugates Market Breakdown, by Technology
10.1.1.4.2 Russia: Europe Antibody Drug Conjugates Market Breakdown, by Application
10.1.1.4.3 Russia: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel

10.1.1.5 Italy: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.5.1 Italy: Europe Antibody Drug Conjugates Market Breakdown, by Technology
10.1.1.5.2 Italy: Europe Antibody Drug Conjugates Market Breakdown, by Application
10.1.1.5.3 Italy: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel

10.1.1.6 Rest of Europe: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.6.1 Rest of Europe: Europe Antibody Drug Conjugates Market Breakdown, by Technology
10.1.1.6.2 Rest of Europe: Europe Antibody Drug Conjugates Market Breakdown, by Application
10.1.1.6.3 Rest of Europe: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Europe Antibody Drug Conjugates Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 ADC Therapeutics SA

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Pfizer Inc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Hoffmann-La Roche Ltd

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 ImmunoGen, Inc

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 GSK Plc

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Gilead Sciences Inc

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 AstraZeneca Plc

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Astellas Pharma Inc

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Takeda Pharmaceutical Co Ltd

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

14. Appendix

14.1 About Business Market Insights